Lesson 08 — about the board
About Legit GLOW
An independent editorial reading of the GLOW peptide literature — what the constituent studies show, where the blend has no data, and what the regulators say.
What Legit GLOW is
Legit GLOW is an independent editorial project that publishes plain-language summaries of the peer-reviewed research literature on the GLOW peptide blend (GHK-Cu + BPC-157 + TB-500) and its three constituent peptides. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
We built this as a teaching board on purpose. A non-standardized three-peptide blend with no trial of its own is exactly the kind of subject where the loudest claims and the actual evidence diverge — so we write the thesis on the board, work each constituent's literature through underneath, and chalk the corrections and the missing data in the margin. The chalk-yellow marks are what the research supports; the dusty-pink marks are the gaps and limits; the blue marks are the verifiable identifiers.
Why "Legit," and what it does not mean
The word "legit" in the name is editorial framing — a due-diligence posture toward the literature, the stance of a reader who wants to know what is actually sourced before believing it. It is not a claim that this site is a legal authority, a pharmacy, a clinic, or a prescriber, and it is not a verdict that the GLOW blend is legitimate as a medicine. Where the evidence is strong we say so plainly; where a claim rests only on a mechanistic rationale or on a single constituent's study, we mark that distinction rather than smoothing it over.
That even-handedness is the entire editorial position. The constituent literature is real and worth reading. The blend itself has no controlled trial, mixed regulatory status, and unstudied combination chemistry [10][14]. A careful board holds both of those truths at once.
How we handle sources
Every quantitative claim on this site is tied to a numbered entry on the references page, and the regulatory statements on the legal-status page are grounded in present-tense FDA sources rather than vendor or clinic reports. Where a widely circulated claim could not be verified from an authoritative source — for example, reports of a 2026 reclassification of these peptides — we do not present it as fact. The board marks what is known, and leaves the unknown visibly blank.